Incyte Corp (INCY)
NASDAQ:INCY
Want to see INCY full AI Analyst Report?
Top Page
Incyte
(NASDAQ:INCY)
Select Model
Select Model
Rating:81Outperform
Price Target:
$113.00
▲(15.52% Upside)
Action:Reiterated
Date:04/29/26
INCY scores well primarily due to strong financial quality (high margins, very low leverage, and robust TTM cash flow) and a generally upbeat earnings call with reaffirmed double-digit growth guidance and meaningful pipeline/regulatory momentum. The score is tempered by historical volatility in profitability/cash flow, elevated R&D spend, and only moderately positive technical signals.
Positive Factors
Low leverage / strong balance sheet
Extremely low debt-to-equity (~0.01) provides durable financial flexibility to fund late-stage trials, multiple launches, and potential M&A without stressing liquidity. This structural strength reduces bankruptcy risk and supports multi-year R&D investment and commercial scale-up even if revenues fluctuate.
Negative Factors
Revenue concentration in Jakafi
A substantial portion of sales remains tied to Jakafi, leaving the company exposed to clinical, competitive, labeling or payor changes. Durable growth requires successful launches (XR, Opzelura, new approvals); any execution miss or market pressure on Jakafi would have outsized impact on cash flow and strategic plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Extremely low debt-to-equity (~0.01) provides durable financial flexibility to fund late-stage trials, multiple launches, and potential M&A without stressing liquidity. This structural strength reduces bankruptcy risk and supports multi-year R&D investment and commercial scale-up even if revenues fluctuate.
Read all positive factors
Incyte Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes revenue from different business units or product lines, highlighting which areas drive growth and profitability, and where strategic focus might be needed.
Analyzes revenue from different business units or product lines, highlighting which areas drive growth and profitability, and where strategic focus might be needed.
Data provided by:
The Fly
The FlyIncyte (INCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.04B
Dividend YieldN/A
Average Volume (3M)1.49M
Price to Earnings (P/E)15.5
Beta (1Y)0.52
Revenue Growth21.48%
EPS Growth1853.63%
CountryUS
Employees2,617
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)7.30
Shares Outstanding199,782,150
10 Day Avg. Volume1,284,756
30 Day Avg. Volume1,494,037
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.73
Price to Sales (P/S)3.75
P/FCF Ratio14.23
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit3.17
Enterprise Value/Ebitda8.34
Forecast
1Y Price Target
$109.13Price Target Upside11.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)7.5
Revenue Forecast (FY)$5.62B
Incyte Business Overview & Revenue Model
Company Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosi...
How the Company Makes Money
Incyte makes money primarily through (1) net product revenues from selling its marketed medicines and (2) collaboration and license revenues from partnerships.
1) Net product revenues (commercial drug sales): Incyte generates the majority of its ...
Incyte Earnings Call Summary
Earnings Call Date:Apr 28, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call presented strong commercial momentum and substantial pipeline/regulatory progress: double‑digit top‑line growth (Q1 revenue +21%, net sales +20%), outsized core ex‑Jakafi growth (+63% YoY), multiple late‑stage programs and regulatory acceptances (povorcitinib, 989 EOP meeting, 734 Phase III) and leadership hires to support launches. Offsetting risks include elevated R&D/operating spend, a small safety review and administrative hold related to pneumonitis in the 734 program, and continued revenue concentration in Jakafi. On balance the positives—robust revenue growth, core business acceleration, and clear late‑stage catalysts—outweigh the lowlights, though execution and safety monitoring remain important near‑term considerations.Positive Updates
Strong Top-Line Growth
Total revenue of $1.27B in Q1 2026, up 21% year-over-year; net sales $1.10B, up 20% YoY. Reaffirmed full-year 2026 net sales guidance of $4.77B–$4.94B (up ~10%–13% vs prior year).
Negative Updates
Elevated R&D and Operating Spend
GAAP R&D rose to $516M (up 18% YoY) as the company invests in late‑stage programs (989, 734, CDK2 etc.). Full‑year guidance for total GAAP R&D and SG&A of $3.495B–$3.675B implies continued heavy investment that could pressure near‑term GAAP profitability and cash burn.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
Total revenue of $1.27B in Q1 2026, up 21% year-over-year; net sales $1.10B, up 20% YoY. Reaffirmed full-year 2026 net sales guidance of $4.77B–$4.94B (up ~10%–13% vs prior year).
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 net sales guidance of $4.77–$4.94 billion (≈10–13% growth), including Jakafi sales of $3.22–$3.27 billion, Opzelura $750–$790 million and hematology/oncology products $800–$880 million; total GAAP R&D plus SG&A operating expenses are guided to $3.495–$3.675 billion, with cost of sales expected to be ~9% of net sales and a revenue mix of ~80% U.S./20% international. In Q1 they reported $1.27 billion total revenue (+21% YoY) and $1.10 billion net sales (+20%), with Jakafi at $758 million (+7%), core business ex‑Jakafi up 63%, hematology/oncology sales $204 million (+116%), GAAP R&D $516 million (+18%) and GAAP SG&A $328 million (+1%); management also highlighted product targets including Jakafi XR approval/launch mid‑2026 (XR could be 10–30% of Jakafi by 2029), Opzelura Europe launch in H2 2026, core ex‑Jakafi potential ~$3–4 billion by 2030 and I&I potentially ~1/3 of total revenue by 2030.Incyte Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.36B | 5.14B | 4.24B | 3.70B | 3.39B | 2.99B |
| Gross Profit | 4.92B | 4.70B | 3.86B | 3.38B | 3.14B | 2.80B |
| EBITDA | 1.87B | 1.76B | 408.16M | 919.43M | 599.64M | 630.20M |
| Net Income | 1.43B | 1.29B | 32.62M | 597.60M | 340.66M | 948.58M |
Balance Sheet | ||||||
| Total Assets | 7.34B | 6.96B | 5.44B | 6.78B | 5.84B | 4.93B |
| Cash, Cash Equivalents and Short-Term Investments | 4.02B | 3.58B | 2.16B | 3.66B | 3.24B | 2.35B |
| Total Debt | 33.83M | 69.43M | 43.54M | 38.29M | 41.46M | 44.82M |
| Total Liabilities | 1.79B | 1.80B | 2.00B | 1.59B | 1.47B | 1.16B |
| Stockholders Equity | 5.55B | 5.17B | 3.45B | 5.19B | 4.37B | 3.77B |
Cash Flow | ||||||
| Free Cash Flow | 1.45B | 1.35B | 249.07M | 449.00M | 892.11M | 568.48M |
| Operating Cash Flow | 1.52B | 1.41B | 335.34M | 496.49M | 969.94M | 749.49M |
| Investing Cash Flow | -191.91M | -102.61M | 157.52M | -207.68M | -78.54M | -207.70M |
| Financing Cash Flow | 198.54M | 101.04M | -2.02B | -20.03M | -794.00K | 6.18M |
Incyte Technical Analysis
Positive
97.82
Price Trends
96.97
Positive
99.41
Negative
92.10
Positive
Market Momentum
0.33
Negative
56.49
Neutral
53.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INCY, the sentiment is Positive. The current price of 97.82 is above the 20-day moving average (MA) of 94.11, above the 50-day MA of 96.97, and above the 200-day MA of 92.10, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 56.49 is Neutral, neither overbought nor oversold. The STOCH value of 53.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INCY.
Incyte Risk Analysis
Incyte disclosed 40 risk factors in its most recent earnings report. Incyte reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Incyte Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | $12.60B | 13.46 | 40.21% | ― | 3.33% | 38.64% | |
81 Outperform | $19.04B | 15.46 | 29.31% | ― | 21.48% | 1853.63% | |
79 Outperform | $24.13B | 23.46 | 19.24% | ― | 5.87% | 8.18% | |
67 Neutral | $10.01B | 25.76 | 4.41% | ― | 12.53% | -49.09% | |
63 Neutral | $15.63B | 77.40 | 20.51% | ― | 21.02% | -24.83% | |
62 Neutral | $15.00B | 4.77 | -5641.90% | ― | 155.14% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
INCY
Incyte
95.31
31.50
49.37%
BMRN
BioMarin Pharmaceutical
51.81
-7.60
-12.79%
EXEL
Exelixis
50.13
5.44
12.17%
UTHR
United Therapeutics
568.58
263.27
86.23%
ASND
Ascendis Pharma
240.50
80.17
50.00%
GMAB
Genmab
26.54
6.36
31.52%
Incyte Corporate Events
Executive/Board Changes
Incyte Announces Upcoming Resignation of Board Member Schaffert
Neutral
Mar 30, 2026
Incyte Corporation announced that board member Susanne Schaffert tendered her resignation from the company’s Board of Directors on March 26, 2026, with the departure to take effect on April 15, 2026. The company stated that Schaffert’s...
Business Operations and StrategyExecutive/Board Changes
Incyte Announces Major Executive Leadership and Commercial Reorganization
Positive
Mar 26, 2026
On March 25, 2026, Incyte announced a series of executive leadership changes designed to support its strategic focus and long-term growth plans. Pablo J. Cagnoni was appointed President, Incyte and Global Head of Research and Development, replacin...
Product-Related AnnouncementsRegulatory Filings and Compliance
Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion
Negative
Mar 6, 2026
On February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter to Incyte for its supplemental Biologics License Application seeking to expand Zynyz’s use to adult patients with metastatic non-small cell lung ca...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.